Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cellsBing Z. Carter, Michael Andreeff, Po Yee Mak et al.|Science Translational Medicine|2016Cited by 172
Survivin is highly expressed in CD34+38− leukemic stem/progenitor cells and predicts poor clinical outcomes in AMLBing Z. Carter, Steven M. Kornblau, Xuelin Huang et al.|Blood|2012Cited by 88
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cellsBing Z. Carter, Michael Andreeff|Oncotarget|2015Cited by 43
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling networkBing Z. Carter, Michael Andreeff|Oncotarget|2016Cited by 38
Application of machine learning methods in clinical trials for precision medicineYizhuo Wang, Xuelin Huang, Bing Z. Carter et al.|JAMIA Open|2022Cited by 35